{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:29:46Z","timestamp":1783560586961,"version":"3.55.0"},"publisher-location":"Chichester, UK","reference-count":139,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd007033.pub2","type":"reference-entry","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T12:25:50Z","timestamp":1317212750000},"source":"Crossref","is-referenced-by-count":30,"title":["Inhaled corticosteroids versus long-acting beta<sub>2<\/sub>-agonists for chronic obstructive pulmonary disease"],"prefix":"10.1002","author":[{"given":"Sally","family":"Spencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Karner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Cates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,5]]},"reference":[{"key":"10.1002\/14651858.CD007033.pub2-BIB1|cit1","series-title":"American Thoracic Society 100th International Conference, May 21-26","first-page":"C22 [Poster 505","article-title":"Lack of interaction between disease severity and therapeutic response with budesonide\/formoterol in a single inhaler [Abstract]","author":"Borgstrom","year":"2004"},{"issue":"6","key":"10.1002\/14651858.CD007033.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB10|cit3","first-page":"iii44","article-title":"Effect of budesonide\/formoterol on severe exacerbations and lung function in moderate to severe COPD","volume":"57 Suppl III","author":"Calverley","year":"2002","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007033.pub2-BIB3|cit4","first-page":"P436","article-title":"Budesonide\/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB4|cit5","first-page":"P1587","article-title":"COPD exacerbations are reduced by budesonide\/formoterol in a single inhaler [Abstract]","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB5|cit6","series-title":"American Thoracic Society 99th International Conference","first-page":"B024 [Poster 41","article-title":"Budesonide\/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]","author":"Calverley","year":"2003"},{"key":"10.1002\/14651858.CD007033.pub2-BIB6|cit7","series-title":"American Thoracic Society 99th International Conference","first-page":"D092 [Poster 21","article-title":"Combining budesonide\/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]","author":"Calverley","year":"2003"},{"key":"10.1002\/14651858.CD007033.pub2-BIB7|cit8","series-title":"American Thoracic Society 2005 International Conference; May 20-25; San Diego, California","first-page":"B93 [Poster 303","article-title":"Budesonide\/formoterol improves the general health status of patients with COPD [Abstract]","author":"Calverley","year":"2005"},{"key":"10.1002\/14651858.CD007033.pub2-BIB8|cit9","first-page":"Poster 1917","article-title":"Budesonide\/formoterol is a well-tolerated long term maintenance therapy for COPD","volume":"26 Suppl 49","author":"Calverley","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB9|cit10","first-page":"P435","article-title":"Budesonide\/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB11|cit11","series-title":"American Thoracic Society 100th International Conference, May 21-26","first-page":"D22 [Poster 525","article-title":"Treatment costs and number needed to treat (NNT) with budesonide\/formoterol to avoid one exacerbation of COPD [Abstract]","author":"Halpin","year":"2004"},{"key":"10.1002\/14651858.CD007033.pub2-BIB12|cit12","series-title":"American Thoracic Society 2005 International Conference; May 20-25; San Diego, California","first-page":"B93 [Poster 314","article-title":"How many patients with COPD must be treated with budesonide\/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]","author":"Halpin","year":"2005"},{"key":"10.1002\/14651858.CD007033.pub2-BIB15|cit13","series-title":"American Thoracic Society 99th International Conference","first-page":"B024 [Poster 41","article-title":"Budesonide\/formoterol in a single inhaler improves health status in patients with COPD [abstract]","author":"Jones","year":"2003"},{"key":"10.1002\/14651858.CD007033.pub2-BIB13|cit14","first-page":"Abstract 1352","article-title":"Budesonide \/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]","volume":"26 Suppl 49","author":"Jones","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB14|cit15","series-title":"13th ERS Annual Congress, 27th September, 2003, Vienna","first-page":"P1586","article-title":"Reducing exacerbations leads to a better health-related quality of life in patients with COPD","author":"Jones","year":"2003"},{"issue":"88","key":"10.1002\/14651858.CD007033.pub2-BIB18|cit16","first-page":"14","article-title":"Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide\/formoterol","volume":"13","author":"Lofdahl","year":"2004","journal-title":"European Respiratory Review"},{"key":"10.1002\/14651858.CD007033.pub2-BIB16|cit17","first-page":"P433","article-title":"Budesonide\/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]","volume":"22 Suppl 45","author":"Lofdahl","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB17|cit18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200523040-00006","article-title":"Cost effectiveness of budesonide\/formoterol in a single inhaler for COPD compared with each monocomponent used alone","volume":"23","author":"Lofdahl","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1002\/14651858.CD007033.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 micro g)\/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007033.pub2-BIB20|cit20","series-title":"Chest","first-page":"S129","article-title":"Salmeterol and fluticasone propionate therapy administered by a single diskus in patients with COPD","author":"Hanania","year":"2002"},{"issue":"5","key":"10.1002\/14651858.CD007033.pub2-BIB21|cit21","first-page":"A279","article-title":"Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus","volume":"163 Suppl","author":"Hanania","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD007033.pub2-BIB22|cit22","first-page":"P434","article-title":"Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg\/fluticasone propionate 250mcg combination [Abstract]","volume":"22 Suppl 45","author":"Horstman","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB23|cit23","series-title":"National COPD Conference; Arlington, Virginia","first-page":"Abstract 1081","article-title":"Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]","author":"Mahler","year":"2003"},{"key":"10.1002\/14651858.CD007033.pub2-BIB24|cit24","first-page":"P429","article-title":"Predicting lung function responses to salmeterol\/fluticasone propionate combination therapy in COPD [Abstract]","volume":"22 Suppl 45","author":"Mahler","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB25|cit25","unstructured":"SFCA3007 A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg\/Fluticasone Propionate 250mcg BID (SFC 50\/250) compared to placebo in COPD subjects GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005"},{"key":"10.1002\/14651858.CD007033.pub2-BIB26|cit26","first-page":"51s","article-title":"Patients with COPD using salmeterol\/fluticasone propionate combination therapy experience improved quality of life","volume":"22 Suppl 45","author":"Spencer","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB27|cit27","first-page":"290s","article-title":"The clinical significance of treatment benefits with the salmeterol\/fluticasone propionate 50\/500mcg combination in COPD","volume":"24 Suppl 48","author":"Spencer","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB28|cit28","unstructured":"Mahler DA Darken P Brown CP Knobil K Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) http:\/\/www.abstracts2view.com 2003"},{"issue":"8","key":"10.1002\/14651858.CD007033.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"American Journal of Respiratory Critical Care Medicine"},{"key":"10.1002\/14651858.CD007033.pub2-BIB30|cit30","unstructured":"SFCA3006 A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg\/Fluticasone Propionate 500mcg BID (SFC 50\/500) compared to placebo in COPD subjects GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005"},{"key":"10.1002\/14651858.CD007033.pub2-BIB31|cit31","first-page":"51","article-title":"Patients with COPD using salmeterol\/fluticasone propionate combination therapy experience improved quality of life","volume":"22 Suppl 45","author":"Spencer","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB32|cit32","series-title":"American Thoracic Society 2005 International Conference; May 20-25; San Diego, California; 2005","first-page":"B93 [Poster 308","article-title":"Salmeterol\/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]","author":"Spencer","year":"2005"},{"key":"10.1002\/14651858.CD007033.pub2-BIB33|cit33","first-page":"290","article-title":"The clinical significance of treatment benefits with the salmeterol\/fluticasone propionate 50\/500mcg combination in COPD","volume":"24 Suppl 48","author":"Spencer","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB34|cit34","first-page":"43","article-title":"Budesonide\/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]","volume":"57 Suppl iii","author":"Anderson","year":"2002","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007033.pub2-BIB35|cit35","series-title":"American Thoracic Society 100th International Conference, May 21-26","first-page":"C22 [Poster 505","article-title":"Lack of interaction between disease severity and therapeutic response with budesonide\/formoterol in a single inhaler [Abstract]","author":"Borgstrom","year":"2004"},{"issue":"3","key":"10.1002\/14651858.CD007033.pub2-BIB36|cit36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1183\/09031936.05.00143404","article-title":"Relationship between respiratory symptoms and medical treatment in exacerbations of COPD","volume":"26","author":"Calverley","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB39|cit37","series-title":"Thorax","first-page":"S145","article-title":"Effect of budesonide\/formoterol on severe exacerbations and lung function in moderate to severe COPD","author":"Calverley"},{"key":"10.1002\/14651858.CD007033.pub2-BIB37|cit38","first-page":"Poster 1917","article-title":"Budesonide\/formoterol is a well-tolerated long term maintenance therapy for COPD","volume":"26 Suppl 49","author":"Calverley","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB38|cit39","first-page":"P435","article-title":"Budesonide\/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB40|cit40","series-title":"Thorax","first-page":"S143","article-title":"Budesonide\/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD","author":"Campbell"},{"key":"10.1002\/14651858.CD007033.pub2-BIB41|cit41","series-title":"Thorax","first-page":"S141","article-title":"Budesonide\/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD","author":"Campell"},{"key":"10.1002\/14651858.CD007033.pub2-BIB42|cit42","first-page":"242 [P1575]","article-title":"Budesonide\/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD","volume":"20 Suppl 38","author":"Dahl","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB43|cit43","first-page":"242 [P1574]","article-title":"Budesonide\/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study","volume":"20 Suppl 38","author":"Egede","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB44|cit44","series-title":"American Thoracic Society 100th International Conference, May 21-26","first-page":"D22 [Poster 525","article-title":"Treatment costs and number needed to treat (NNT) with budesonide\/formoterol to avoid one exacerbation of COPD [Abstract]","author":"Halpin","year":"2004"},{"key":"10.1002\/14651858.CD007033.pub2-BIB45|cit45","first-page":"250 [P1613]","article-title":"Improvement in health status in patients with moderate to severe COPD after treatment with budesonide\/formoterol in a single inhaler","volume":"20 Suppl 38","author":"Jones","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB46|cit46","first-page":"242 [P1577]","article-title":"Budesonide\/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD","volume":"20 Suppl 38","author":"Korsgaard","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB47|cit47","first-page":"242 [P1573]","article-title":"Budesonide\/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study","volume":"20 Suppl 38","author":"Lange","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"88","key":"10.1002\/14651858.CD007033.pub2-BIB48|cit48","first-page":"14","article-title":"Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide\/formoterol","volume":"13","author":"Lofdahl","year":"2004","journal-title":"European Respiratory Review"},{"key":"10.1002\/14651858.CD007033.pub2-BIB49|cit49","first-page":"242 [P1576]","article-title":"Budesonide\/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD","volume":"20 Suppl 38","author":"Milanowski","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD007033.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB51|cit51","unstructured":"AstraZeneca A 6-month double-blind, double-dummy, randomized, parallel group, multicenter efficacy & safety study of SYMBICORT\u00ae pMDI 2 x 160\/4.5 \u03bcg & 80\/4.5 \u03bcg bid compared to formoterol TBH, budesonide pMDI (& the combination) & placebo in COPD Patients (SHINE) (study number D589900002) www.astrazenecaclinicaltrials.com 2007"},{"key":"10.1002\/14651858.CD007033.pub2-BIB52|cit52","doi-asserted-by":"crossref","unstructured":"Bleecker ER Meyers DA Bailey WC Sims AM Bujac SR Goldman M Effect Of \u00df2-Adrenergic Receptor Gene Polymorphism Gly16Arg On Response To Budesonide\/Formoterol Pressurized Metered-Dose Inhaler In Chronic Obstructive Pulmonary Disease [Abstract] American Journal of Respiratory and Critical Care Medicine 2011 A4086","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A4086"},{"key":"10.1002\/14651858.CD007033.pub2-BIB53|cit53","doi-asserted-by":"crossref","unstructured":"Tashkin DP Rennard SI Martin P Ramachandran S Martin UJ Silkoff PE Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial Drugs 2008 1975 2000","DOI":"10.2165\/00003495-200868140-00004"},{"key":"10.1002\/14651858.CD007033.pub2-BIB54|cit54","doi-asserted-by":"crossref","unstructured":"Briggs AH GHA L-OG SM CPMA JPW Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study European Respiratory Journal 2010 532 9","DOI":"10.1183\/09031936.00153108"},{"key":"10.1002\/14651858.CD007033.pub2-BIB55|cit55","first-page":"A149","article-title":"The TOwards a Revolution in COPD Health (TORCH) study: salmeterol\/fluticasone propionate improves survival in COPD over three years","volume":"11 Suppl 5","author":"Calverley","year":"2006","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD007033.pub2-BIB56|cit56","doi-asserted-by":"crossref","unstructured":"Calverley PM AJA CB FGT JC JPW Cardiovascular events in patients with COPD: TORCH study results Thorax 2010 719 25","DOI":"10.1136\/thx.2010.136077"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.1378\/chest.130.4_MeetingAbstracts.122S-a","article-title":"The towards a revolution in COPD health (TORCH) study: fluticasone propionate \/salmeterol improves survival in COPD over three years","volume":"130","author":"Calverley","year":"2006","journal-title":"Chest"},{"issue":"8","key":"10.1002\/14651858.CD007033.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007033.pub2-BIB59|cit59","first-page":"34","article-title":"The TORCH (towards a revolution in COPD health) study salmeterol\/fluticasone propionate (SFC) improves survival in COPD over three years","volume":"28 Suppl 50","author":"Calverley","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB60|cit60","first-page":"578s","article-title":"Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study","volume":"22 Suppl 45","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB61|cit61","first-page":"A140","article-title":"The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol\/fluticasone propionate reduces the rate of exacerbations over three years","volume":"11 Suppl 5","author":"Celli","year":"2006","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD007033.pub2-BIB62|cit62","first-page":"34s","article-title":"The TORCH (TOwards a Revolution in COPD Health) study: salmeterol\/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years","volume":"28 Suppl 50","author":"Celli","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB63|cit63","series-title":"Proceeedings of the American Thoracic Society","first-page":"A320 (Poster 32","article-title":"Fluticasone propionate\/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC\/TLC) and exercise endurance time in patients with COPD.","author":"Celli","year":"2006"},{"key":"10.1002\/14651858.CD007033.pub2-BIB64|cit64","doi-asserted-by":"crossref","unstructured":"Celli B Vestbo J Jenkins CR Jones PW Ferguson GT Calverley PMA Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: The TORCH experience American Journal of Respiratory and Critical Care Medicine 2011 317 22","DOI":"10.1164\/rccm.201004-0665OC"},{"key":"10.1002\/14651858.CD007033.pub2-BIB65|cit65","first-page":"764 [4395]","article-title":"Salmeterol\/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC\/TLC) and exercise endurance time in patients with COPD","volume":"28 Suppl 50","author":"Celli","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB66|cit66","first-page":"230","article-title":"Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health)","volume":"62","author":"Corhay","year":"2007","journal-title":"Revue Medicale de Liege"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB68|cit67","doi-asserted-by":"crossref","first-page":"178s","DOI":"10.1378\/chest.130.4_MeetingAbstracts.178S-a","article-title":"The towards a revolution in COPD health (TORCH) study: fluticasone propionate\/salmeterol is well tolerated in patients with COPD over 3 years","volume":"130","author":"Ferguson","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007033.pub2-BIB69|cit68","first-page":"34s","article-title":"The TORCH (TOwards a Revolution in COPD Health) study: salmeterol\/fluticasone propionate (SFC) improves survival in COPD over three years","volume":"28 Suppl 50","author":"Ferguson","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB67|cit69","unstructured":"Ferguson GT CPM AJA JCR CB Prevalence and progression of osteoporosis in patients with COPD results from the Towards a Revolution in COPD Health Study Chest 2009 1456 65"},{"key":"10.1002\/14651858.CD007033.pub2-BIB70|cit70","unstructured":"Jenkins CR Calverley PMA Celli B Ferguson G Jones PW Pride N Seasonal patterns of exacerbation rates in the TORCH survival study http:\/\/www.abstracts2view.com 2007 A839"},{"key":"10.1002\/14651858.CD007033.pub2-BIB71|cit71","doi-asserted-by":"crossref","unstructured":"Jones PW Calverley P Celli B Ferguson G Jenkins C Pride N Trans-Regional Validity of the SGRQ in the TORCH Survival Study http:\/\/www.abstracts2view.com 2007 A122","DOI":"10.1378\/chest.130.4_MeetingAbstracts.122S-a"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB72|cit72","doi-asserted-by":"crossref","first-page":"177s","DOI":"10.1016\/S0012-3692(16)51794-2","article-title":"The towards study a revolution in COPD health (TORCH) study: fluticasone propionate\/salmeterol improves and sustains health status in COPD over 3 years","volume":"130","author":"Jones","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007033.pub2-BIB73|cit73","doi-asserted-by":"crossref","unstructured":"Keene ON VJ AJA CPMA CB FGT Methods for therapeutic trials in COPD: Lessons from the TORCH trial European Respiratory Journal 2009 1018 23","DOI":"10.1183\/09031936.00122608"},{"key":"10.1002\/14651858.CD007033.pub2-BIB74|cit74","doi-asserted-by":"crossref","unstructured":"McDonough C BAR TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease Hospital Practice 2010 92 3","DOI":"10.3810\/hp.2010.04.299"},{"key":"10.1002\/14651858.CD007033.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/thx.2006.072348","article-title":"Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee","volume":"62","author":"McGarvey","year":"2007","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007033.pub2-BIB76|cit76","unstructured":"SCO30003 A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol\/fluticasone propionate (SERETIDE\u00ae\/VIANI\u00ae\/ADVAIR\u00ae) 50\/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS\u00ae\/ACCUHALER\u00ae inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment www.ctr.gsk.co.uk 2006"},{"key":"10.1002\/14651858.CD007033.pub2-BIB77|cit77","doi-asserted-by":"crossref","unstructured":"Vestbo J AJA CPMA CB FGT JC Bias due to withdrawal in long-term randomised trials in COPD: Evidence from the TORCH study Clinical Respiratory Journal 2011 44 9","DOI":"10.1111\/j.1752-699X.2010.00198.x"},{"issue":"2","key":"10.1002\/14651858.CD007033.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1183\/09031936.04.00120603","article-title":"The TORCH (TOwards a Revolution in COPD Health) survival study protocol","volume":"24","author":"Vestbo","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB79|cit79","unstructured":"Wise RA McGarvey LP John M Anderson JA Zvarich MT Reliability of cause-specific mortality adjudication in a COPD clinical trial http:\/\/www.abstracts2view.com 2007 A120"},{"issue":"9356","key":"10.1002\/14651858.CD007033.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007033.pub2-BIB81|cit81","unstructured":"Calverley PMA Pauwels RA Vestbo J Jones PW Pride NB Gulsvik A Clinical improvements with salmeterol \/ fluticasone propionate combination in differing severities of COPD http:\/\/www.abstracts2view.com 2003 A035 [Poster D50]"},{"key":"10.1002\/14651858.CD007033.pub2-BIB82|cit82","series-title":"Proceedings of the 98th International American Thoracic Society Conference http:\/\/www.abstracts-on-line.com\/abstracts\/ATS","first-page":"A98 [Poster 306","article-title":"Salmeterol\/fluticasone propionate combination for one year provides greater clinical benefit than its individual components","author":"Calverley","year":"2002"},{"key":"10.1002\/14651858.CD007033.pub2-BIB83|cit83","first-page":"242 [P1572]","article-title":"Safety of salmeterol\/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease","volume":"20 Suppl 38","author":"Calverly","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB84|cit84","series-title":"American Thoracic Society 100th International Conference, May 21-26","first-page":"D22 [Poster 503","article-title":"Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol\/fluticasone propionate combination (SFC) and associated costs [Abstract]","author":"Hunjan","year":"2004"},{"key":"10.1002\/14651858.CD007033.pub2-BIB85|cit85","first-page":"291","article-title":"Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol\/ fluticasone propionate combination (Seretide) and salmeterol","volume":"24 Suppl 48","author":"Hunjan","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB86|cit86","first-page":"513s","article-title":"Salmeterol\/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate\/severe COPD","volume":"24 Suppl 48","author":"Hunjan","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB87|cit87","series-title":"Proceedings of the 98th International American Thoracic Society Conference http:\/\/www.abstracts-on-line.com\/abstracts\/ATS","first-page":"A39 [Poster K39","article-title":"Salmeterol\/fluticasone propionate combination improves health status in COPD patients","author":"Jones","year":"2002"},{"key":"10.1002\/14651858.CD007033.pub2-BIB88|cit88","first-page":"Abstract 1352","article-title":"Budesonide \/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]","volume":"26 Suppl 49","author":"Jones","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB89|cit89","series-title":"13th ERS Annual Congress, 27 Spetember 2003, Vienna","first-page":"P1593","article-title":"Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study","author":"Jones","year":"2003"},{"issue":"6","key":"10.1002\/14651858.CD007033.pub2-BIB90|cit90","first-page":"727","article-title":"Inhalational combination therapy in chronic obstructive lung disease. Tristan study","volume":"45","author":"Nitschmann","year":"2004","journal-title":"German Internist"},{"key":"10.1002\/14651858.CD007033.pub2-BIB91|cit91","unstructured":"Pauwels R Vestbo J Calverley PMA Jones PW Pride NB Gulsvik A Characterization of exacerbations in the TRISTAN study of salmeterol \/ fluticasone propionate (SFC) combination in moderate to severe COPD http:\/\/www.abstracts2view.com 2003"},{"key":"10.1002\/14651858.CD007033.pub2-BIB92|cit92","first-page":"240 [P1569]","article-title":"Reduction of exacerbations with salmeterol\/fluticasone combination 50\/500 mcg bd in the treatment of chronic obstructive pulmonary disease","volume":"20 Suppl 38","author":"Pauwels","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB93|cit93","unstructured":"SFCB3024 A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol\/FP combination product at a strength of 50\/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS\u2122\/ACCUHALER\u2122, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk) 2005"},{"issue":"6","key":"10.1002\/14651858.CD007033.pub2-BIB94|cit94","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00019053-200523060-00008","article-title":"Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease","volume":"23","author":"Spencer","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD007033.pub2-BIB95|cit95","first-page":"290","article-title":"The clinical significance of treatment benefits with the salmeterol\/fluticasone propionate 50\/500mcg combination in COPD","volume":"24 Suppl 48","author":"Spencer","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB96|cit96","first-page":"240 [P1570]","article-title":"Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease","volume":"20 Suppl 38","author":"Vestbo","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/thx.2004.025411","article-title":"Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease","volume":"60","author":"Vestbo","year":"2005","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007033.pub2-BIB98|cit98","unstructured":"Vestbo J Pauwels RS Calverley PMA Jones PW Pride NB Gulsvik A Salmeterol \/ fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD http:\/\/www.abstracts2view.com 2003"},{"issue":"11","key":"10.1002\/14651858.CD007033.pub2-BIB99|cit99","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.rmed.2004.03.017","article-title":"Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD","volume":"98","author":"Vestbo","year":"2004","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD007033.pub2-BIB100|cit100","series-title":"American Thoracic Society International Conference","first-page":"B93 [Poster 320","article-title":"Salmeterol\/fluticasone propionate (SFC) anti-inflammatory effects in COPD","author":"Barnes","year":"2005"},{"key":"10.1002\/14651858.CD007033.pub2-BIB101|cit101","first-page":"P1859","article-title":"Formoterol\/budesonide (FBC) in the treatment of acute exacerbations of COPD","volume":"22 Suppl 45","author":"Cazzola","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB102|cit102","first-page":"252","article-title":"Efficacy of a combination therapy with single inhaler budesonide\/formoterol in the treatment of acute exacerbations of COPD","volume":"24 Suppl 48","author":"Cazzola","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB103|cit103","first-page":"177","article-title":"Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease","volume":"18 Suppl 33","author":"Della Cioppa","year":"2001","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB104|cit104","first-page":"515","article-title":"The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use","volume":"18 Suppl 33","author":"Greefhorst","year":"2001","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB105|cit105","first-page":"514","article-title":"Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use","volume":"18 Suppl 33","author":"Kristufek","year":"2001","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB106|cit106","first-page":"Poster J15","article-title":"Effect of 6 months therapy with inhaled fluticasone propionate (FP) with or without salmeterol (S) on bronchial inflammation in COPD","volume":"A111","author":"Gosman","year":"2006","journal-title":"Proceedings of the American Thoracic Society"},{"key":"10.1002\/14651858.CD007033.pub2-BIB107|cit107","unstructured":"Jiang Y XW WH ZH ZY XX Effects of salmeterol\/fluticasone propionate on inflammation and innate immunity in COPD [Abstract] Respirology 2009 A159 [OS 25-03]"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB108|cit108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF03256618","article-title":"Inhaled salmeterol\/fluticasone propionate combination in chronic obstructive pulmonary disease","volume":"1","author":"Lyseng-Williamson","year":"2002","journal-title":"American Journal of Respiratory Medicine"},{"key":"10.1002\/14651858.CD007033.pub2-BIB109|cit109","unstructured":"Mittmann N HP MC BL WT Cost-effectiveness of budesonide\/formoterol added to tiotropium in COPD patients in Canada, Australia and Sweden [Abstract] European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22 2010 [5183]"},{"key":"10.1002\/14651858.CD007033.pub2-BIB110|cit110","unstructured":"Nungtjik AK MH YF AB Efficacy of combination of fluticasone propionate\/salmeterol in a single inhaler (Diskus) on chronic obstructive pulmonary disease [Abstract] Respirology 2009 A268 [PO 033]"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB111|cit111","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00003495-200464040-00006","article-title":"Budesonide\/formoterol in chronic obstructive pulmonary disease","volume":"64","author":"Reynolds","year":"2004","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD007033.pub2-BIB112|cit112","unstructured":"Tzani P CE NG CE AM CA Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD [Abstract] European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22 2010 [P1204]"},{"key":"10.1002\/14651858.CD007033.pub2-BIB113|cit113","doi-asserted-by":"crossref","unstructured":"Worth H FK PS NU MH Budesonide\/formoterol improves exercise tolerance compared with placebo and formoterol in COPD patients [Abstract] European Respiratory Society Annual Congress, Vienna, Austria, September 12-16 2009 [201]","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A6193"},{"issue":"2","key":"10.1002\/14651858.CD007033.pub2-BIB114|cit114","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1378\/chest.09-1305","article-title":"Inhaled corticosteroids vs placebo for preventing COPD exacerbations","volume":"137","author":"Agarwal","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD007033.pub2-BIB115|cit115","article-title":"Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease","author":"Appleton","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007033.pub2-BIB116|cit116","unstructured":"Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society American Journal of Respiratory and Critical Care Medicine 1995 S77 121"},{"key":"10.1002\/14651858.CD007033.pub2-BIB117|cit117","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1183\/09031936.97.10040815","article-title":"An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)","volume":"10","author":"Boyd","year":"1997","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB118|cit118","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007033.pub2-BIB119|cit119","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD007033.pub2-BIB120|cit120","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007033.pub2-BIB121|cit121","doi-asserted-by":"crossref","unstructured":"Quanjer PH Tammeling GJ Cotes JE Pedersen OF Peslin R Yernault JC Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society European Respiratory Journal 1993 5 40","DOI":"10.1183\/09041950.005s1693"},{"key":"10.1002\/14651858.CD007033.pub2-BIB122|cit122","unstructured":"Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from http:\/\/www.goldcopd.com 2010"},{"key":"10.1002\/14651858.CD007033.pub2-BIB123|cit123","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD007033.pub2-BIB124|cit124","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007033.pub2-BIB125|cit125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00161507","article-title":"Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited","volume":"32","author":"Keene","year":"2008","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007033.pub2-BIB126|cit126","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","article-title":"Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease","volume":"343","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB127|cit127","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease","author":"Nannini","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB128|cit128","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease","author":"Nannini","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB129|cit129","article-title":"Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease","author":"Nannini Luis","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007033.pub2-BIB130|cit130","unstructured":"National Clinical Guideline Centre Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care 2010"},{"issue":"25","key":"10.1002\/14651858.CD007033.pub2-BIB131|cit131","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease","volume":"340","author":"Pauwels","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007033.pub2-BIB132|cit132","unstructured":"Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration Review Manager (RevMan) Version 5.1 2008"},{"issue":"5","key":"10.1002\/14651858.CD007033.pub2-BIB133|cit133","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1378\/chest.07-1167","article-title":"Safety of long-acting \u03b2-agonists in stable COPD*","volume":"133","author":"Rodrigo","year":"2008","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD007033.pub2-BIB134|cit134","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1378\/chest.09-0821","article-title":"Safety and Efficacy of Combined Long-Acting \u03b2-Agonists and Inhaled Corticosteroids vs Long-Acting \u03b2-Agonists Monotherapy for Stable COPD","volume":"136","author":"Rodrigo","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007033.pub2-BIB135|cit135","doi-asserted-by":"crossref","unstructured":"Singh S LYK An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease International Journal of Chronic Obstructive Pulmonary Disease 2010 189 95","DOI":"10.2147\/COPD.S6942"},{"key":"10.1002\/14651858.CD007033.pub2-BIB136|cit136","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1164\/ajrccm.163.1.2005009","article-title":"Health status deterioration in patients with COPD","volume":"163","author":"Spencer","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD007033.pub2-BIB137|cit137","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/thorax.58.7.589","article-title":"Time course of recovery of health status following an infective exacerbation of chronic bronchitis","volume":"58","author":"Spencer","year":"2003","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007033.pub2-BIB138|cit138","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(98)10019-3","article-title":"Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial","volume":"353","author":"Vestbo","year":"1999","journal-title":"The Lancet"},{"issue":"2","key":"10.1002\/14651858.CD007033.pub2-BIB139|cit139","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002991.pub2","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007033.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T23:55:47Z","timestamp":1686354947000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007033.pub2"}},"subtitle":[],"editor":[{"given":"Sally","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,10,5]]},"references-count":139,"aliases":["10.1002\/14651858.cd007033.pub3"],"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007033.pub2","relation":{},"subject":[],"published":{"date-parts":[[2011,10,5]]}}}